Menu Search
Equities

Lepu Biopharma Co Ltd

2157:HKG.HZ

Lepu Biopharma Co Ltd

Actions
  • Price (HKD)4.47
  • Today's Change-0.05 / -1.11%
  • Shares traded2.76m
  • 1 Year change-23.06%
  • Beta--
Data delayed at least 15 minutes, as of May 29 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.

  • Revenue in HKD (TTM)242.86m
  • Net income in HKD-23.81m
  • Incorporated2018
  • Employees429.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.